Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bezlotoxumab and Actoxumab in Clostridioides Difficile Infection (MODIFY II)
NCT01513239Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Primary completion
- May 2015
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 3 trial of bezlotoxumab, actoxumab in Clostridioides difficile infection (CDI), sponsored by Merck & Co.. Started Feb 2012; status: completed.
02
Drugs
bezlotoxumabactoxumab
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT01513239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513239.